Biosimilar Newsletter Archive

31. 11.03.20 -- New Podcast Episodes: CAR T Therapy Cost Control, Gap Analysis, And More 11/3/2020
    11/03/20 Biosimilar Development Newsletter
32. 10.29.20 -- Is Biopharma Suffering From Thalassophobia? 10/29/2020
    10/29/20 Biosimilar Development Newsletter
33. 10.28.20 -- Solve Viral Vector Vaccine Development Challenges 10/28/2020
    10/28/20 Biosimilar Development Newsletter
34. 10.24.20 -- How Drug Development Benefits From End-To-End Thinking 10/24/2020
    10/24/20 Biosimilar Development Newsletter
35. 10.23.20 -- Cell & Gene Therapy Workflows, Built On A History Of Bioprocessing 10/23/2020
    10/23/20 Biosimilar Development Newsletter
36. 10.22.20 -- Rituxan Biosimilars: Market & Clinical Considerations 10/22/2020
    10/22/20 Biosimilar Development Newsletter
37. 10.19.20 -- How Drug Development Benefits From End-To-End Thinking 10/19/2020
    10/19/20 Biosimilar Development Newsletter
38. 10.15.20 -- The Intriguing FDA News You May Have Missed 10/15/2020
    10/15/20 Biosimilar Development Newsletter
39. 10.14.20 -- Droplet Digital PCR QXDx BCR-ABL Kit Takes MRD To The Next Level 10/14/2020
    10/14/20 Biosimilar Development Newsletter
40. 10.09.20 -- Bioprocess Intensification Resources And Best Practices 10/9/2020
    10/09/20 Biosimilar Development Newsletter